CN1237177C - Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent - Google Patents
Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent Download PDFInfo
- Publication number
- CN1237177C CN1237177C CN 03126758 CN03126758A CN1237177C CN 1237177 C CN1237177 C CN 1237177C CN 03126758 CN03126758 CN 03126758 CN 03126758 A CN03126758 A CN 03126758A CN 1237177 C CN1237177 C CN 1237177C
- Authority
- CN
- China
- Prior art keywords
- adenovirus
- construction body
- cell
- tumour
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 78
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 title abstract description 18
- 108010056274 polo-like kinase 1 Proteins 0.000 title abstract description 18
- 241000700605 Viruses Species 0.000 title description 7
- 210000004907 gland Anatomy 0.000 title description 7
- 230000001093 anti-cancer Effects 0.000 title description 5
- 230000000415 inactivating effect Effects 0.000 title description 3
- 239000000470 constituent Substances 0.000 title 1
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 176
- 238000010276 construction Methods 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000012408 PCR amplification Methods 0.000 claims abstract 3
- 238000012217 deletion Methods 0.000 claims abstract 3
- 230000037430 deletion Effects 0.000 claims abstract 3
- 108091026890 Coding region Proteins 0.000 claims abstract 2
- 230000006798 recombination Effects 0.000 claims description 42
- 238000005215 recombination Methods 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 29
- 108020004414 DNA Proteins 0.000 claims description 22
- 230000008034 disappearance Effects 0.000 claims description 22
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 238000001415 gene therapy Methods 0.000 claims description 20
- 239000013612 plasmid Substances 0.000 claims description 19
- 108091008146 restriction endonucleases Proteins 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 101710199711 Early E1A protein Proteins 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 claims 2
- 101710192606 Latent membrane protein 2 Proteins 0.000 claims 1
- 101710109576 Terminal protein Proteins 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 239000013605 shuttle vector Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 92
- 210000004881 tumor cell Anatomy 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 24
- 238000011282 treatment Methods 0.000 abstract description 21
- 238000001890 transfection Methods 0.000 abstract description 12
- 238000000746 purification Methods 0.000 abstract description 7
- 108091036078 conserved sequence Proteins 0.000 abstract description 4
- 238000013459 approach Methods 0.000 abstract description 3
- 230000000981 bystander Effects 0.000 abstract description 3
- 239000002299 complementary DNA Substances 0.000 abstract description 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000006801 homologous recombination Effects 0.000 abstract description 2
- 238000002744 homologous recombination Methods 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 description 49
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 27
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 19
- 238000005119 centrifugation Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 14
- 238000000502 dialysis Methods 0.000 description 13
- 235000015097 nutrients Nutrition 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000005336 cracking Methods 0.000 description 10
- 230000024835 cytogamy Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000009849 deactivation Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000011435 rock Substances 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000009126 molecular therapy Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000006209 dephosphorylation reaction Methods 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 206010013183 Dislocation of vertebra Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000030609 dephosphorylation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000000064 prostate epithelial cell Anatomy 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 2
- 208000004179 Oral Leukoplakia Diseases 0.000 description 2
- 101150020201 RB gene Proteins 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000008557 oral mucosa leukoplakia Diseases 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 108700025694 p53 Genes Proteins 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 101100192829 Arabidopsis thaliana PXC1 gene Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010093502 E2F Transcription Factors Proteins 0.000 description 1
- 102000001388 E2F Transcription Factors Human genes 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 101150010855 cma gene Proteins 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- GDPJWJXLKPPEKK-SJAYXVESSA-N dT4 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 GDPJWJXLKPPEKK-SJAYXVESSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 101150073897 plk1 gene Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention discloses a construction scheme for artificially modifying a human 5 type adenovirus (ADV5), and a specific purpose of a recombinant adenovirus construction body obtained by the scheme in tumor treatment. The techniques of PCR amplification point-fixed deletion, homologous recombination, transfection, adenovirus monoclone purification, etc., are used to obtain the recombinant adenovirus construction body which is characterized in that nine bases of the coding sequence of an ADV5 genome E1A conserved sequence 2 (CR2) are deleted; the 28532 to 29360 nt in ADV5E3 area is deleted, and a PLK1 cDNA segment is reversedly inserted into the area. The recombinant adenovirus construction body can be selectively reproduced and proliferated in a tumor cell; the inserted reverse PLK1 cDNA segment is specifically expressed in the tumor cell; the recombinant adenovirus construction body has a strong bystander effect on the tumor cell, and therefore, the recombinant adenovirus construction body can kill tumor cells specifically without hurting normal cells. The construction body has unique practical value in the preparation of medicines and diagnostic reagents for treating tumors, and at the same time, the recombinant adenovirus construction body also provides an ideal gene target specificity treatment application approach for tumor gene treatment.
Description
One, technical field
The present invention relates to a kind of human 5 type adenovirus (Human adenovirus type 5, ADV5) constructing plan of recombinant chou, its technical characterictic is: the genomic 923-931nt sequence of directed disappearance ADV5 (CTT ACC TGC, this sequence encoding E1A protein 12 2 to 124 amino acids), on this basis, further disappearance ADV5 E3 district 28532-29360nt introduces a ClaI restriction enzyme site in this disappearance zone; In the ClaI restriction enzyme site, oppositely insert the exogenous PLK1cDNA fragment (960-161nt that is equivalent to PLK1mRNA) of 820bp, thereby obtain the recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 that tumour is had therapeutic action.Summary of the invention belongs to the cma gene field of engineering technology.
Two, background technology
Malignant tumour is becoming the primary disease of harm humans health.Show according to latest domestic epidemiology survey data: China has cancer patient more than 300 ten thousand people now, the patient who dies from malignant tumour every year is about 1,300,000 people, the malignant tumour case that 1,600,000 to 2,000,000 New Developments are arranged every year, and with 3% speed increase, cause grave danger for China people's life and health, restricted the Sustainable development of China's economy to a certain extent.At present, the treatment of most kinds of tumor still is faced with stern challenge, and conventional oncotherapy means can't fundamentally be removed malignant tumour, therefore, press on tumor therapeuticing method and innovate.
Under the new historical conditions that molecular mechanism is understood gradually, tumour molecular medicine theory and methodological breakthrough have caused the trial of a series of development novel tumors treatment patterns in tumor invasion.The new drug Gleevec that is used for the treatment of chronic myelocytic leukemia formally becomes the clinical prescription medicine, a large amount of molecular target specificity anticancer compounds enter clinic trial, the weight break point of a key that indicated breaking through to of oncotherapy, and phasic results have been obtained, tentatively highlight the elementary contour that following tumour problem solves, its the most one of the solution of core to from the complicated gene regulatory network of tumour, decomposite the most key molecular target exactly, implement molecular targeted treatment.At the bottom of calendar year 2001, obtain the FDA approval and enter the molecular therapy kind in clinical experiment stage above 3,000 kinds, comprise cell conduction block agent, angiogenesis inhibitor, tumor vaccine and monoclonal antibody, for the final solution of tumour problem has brought new hope, we can say, following human tumor effectively to be controlled at the development that fundamentally relies on molecular therapy perfect.
The main means of molecular therapy are divided three classes: monoclonal antibody, micromolecular compound and gene therapy.
Gene therapy has been widely used in the clinical trial treatment of kinds of tumors as having most one of part of vitality in the medical field development in recent years, demonstrates good prospects for application.The end of the year from 1989 to 2000, U.S.'s center for biologic evaluation and research (Center for Biologics Evaluations andResearch, CBER) Pi Zhun clinical gene therapy test subject is above 350, it is therapy of tumor that 70% project is wherein arranged approximately, part has entered the III clinical trial phase, obtain better curative effect, under the promotion of huge medical requirement, the gene therapy preparation might become the clinical treatment medicine by official listing in the several years, become an indispensable integral part of the existing treatment system of tumour.
One of carrier that reorganization ADV5 carrier is most widely used as therapy of tumor, its Clinical feasibility and security have obtained generally acknowledged, adenoviral gene treatment carrier has following outstanding biology advantage and clinical application advantage: (1) pattern of infection is wide, to multiple tissues-derived tumour cell, no matter be in division stage or the cell of stationary phase, all can effectively attack, therefore, anticancer spectrum is wide; (2) after ADV-TK enters cell, exist with extrachromosomal form, do not have sudden change, carcinogenic danger, clinical application safety only produces similar cold like symptoms after the use, no hemopoietic function and immunologic function inhibition; (3) clinical application is convenient, can pass through approach such as direct injection (one or more) and interventional therapy application in lacuna (abdominal cavity, thoracic cavity and cranial cavity etc.) administration, part or the knurl body; (4) in ADV-TK continuous expression 2-3 week only in cell paste, especially be fit to oncotherapy; (5) only produce slight inflammatory reaction after vein or topical application, side effect is slight; (6) adenovirus of clinical grade quantity, quality is easy to production, purifying.
Clinical tumor most carriers on probation are the replication defective sexual gland virus that has lacked E1 and E3 district at present, after entering tumor focus, the killing effect of tumour is depended on the input of external high density treatment adenovirus, the killing effect of the focus far away apart from injection point a little less than.For this reason, in recent years, occurred from the new development trend of replication defective sexual gland virus carrier to condition replicability adenovirus carrier (conditionally replicativeadenovirus) conversion, so-called condition replicability adenovirus carrier is meant that carrier can optionally duplicate propagation in tumour cell, with the place of tumour cell as the production adenovirus, finally reach cracking and kill the therapeutic purpose of tumour cell, after the tumour cell cracking discharges the adenovirus of high density, can further infect the focus tumour cell far away apart from injection point, form the infection ripple of a new round, going round and beginning again forms a kind of positive regeeration, reaches maximum treatment effect.Examples of such carriers another very the ideal advantage be that they can not be finished in normal cell and duplicate, therefore normal cell is not had any lethal effect, some authoritative medical journal is generically likened it to the SmartBombs (smart bomb) of killing tumour.In the practical application, obtained desired result preferably.In the 21st U.S.'s tumor research annual meeting, a research report from Houston Anderson tumor center shows: behind the local injection, the distribution of replication defective sexual gland virus in human malignant glioma focus be limitation, influenced the performance of curative effect to a certain extent, form a sharp contrast therewith, the adenovirus ONYX-015 that can duplicate at specifically inside tumor cell is by the propagation at tumor by local, its distribution spreads all over full knurl kitchen range, obtains significant curative effect.ONYX-015 be U.S. ONYX Pharma Biotech develop in recent years can be in tumour cell the adenovirus of copy choice, its structure characteristics are on the genome of the human 5 type adenovirus (wild-type) of wild-type, the encoding sequence of excalation (delete) E1B 55 kDa, and add the translation termination signal, but keep the encoding sequence of 19kDa E1B.Under normal circumstances, wild-type adenovirus depends on the deactivation of E1B 55kDa albumen to the p53 protein function in the intracellular propagation of duplicating.For the normal cell that carries normal p53 gene, ONYX-015 can not breed in time multiplexed cell system owing to lack E1B 55kDa; On the contrary, because the inactivation rate of malignant tumor patient p53 gene is up to 50-70%, ONYX-015 thereby can in tumour cell, breed and duplicate final lysing cell, thereby ONYX-015 has the high selectivity of killing tumour cell, and normal cell is not had lethal effect.
As the ONYX-015 of condition replicability adenovirus carrier representative products since entering clinical trial in 1996, obtained very challenging clinical efficacy, internationally famous medical journals " The Lancet " is being in the commentary of topic with " the new hope of gene therapy ", the potential applicability in clinical practice of high evaluation ONYX-015, international foremost medical journals has been delivered clinical test results and commentary article as " Science ", " Nature Medicine ".At present, Pfizer (pfizer) pharmaceutical companies has been bought from ONYX biotech company and has been used patent, and kinds of tumors has been carried out clinical phase test, wherein, to recurrent, the treatment of intractable tumor of head and neck is just being carried out the clinical III phase and is being tested, obtained very satisfied curative effect, to other tumours such as transitivity colorectal carcinoma, lung cancer, carcinoma of the pancreas, the clinical I-II phase of oral leukoplakia (oral leukoplakia) and glioblastoma is tested well afoot, simultaneously, it is that some relevant gene therapy recombinant adenoviral vectors of carrier are (as inserting therapeutic gene TK that ONYX has obtained with ONYX-015, CD) patent is just tested transition from the preclinical phase test to the clinical phase.Can predict, ONYX-015 and relevant gene therapy product thereof will formally enter clinical application in the U.S. in the near future, demonstrate very good potential applicability in clinical practice in the clinical development product of gene therapy for cancer.The domestic patent application that has 4 examples and ONYX-015 similar principles: patent application " a kind of defective adenoviral and construction process thereof " (application number is 99124030.8) is positioned at the 2809-3329bp encoding sequence by disappearance E1B 55kDa, and obtains the construct of E1B 55kDa excalation in the method for disappearance position insertion stop code; Patent application " structure of disappearance apoptosis suppressor virus and the application in therapy of tumor " (application number is 98113494.7), by excalation E1B55kDa encoding sequence, and at this disappearance position insertion marker gene LacZ, obtain E1B 55kDa excalation and carry the adenovirus construct of marker gene simultaneously, another characteristics of this construct are disappearances that the E3 district is arranged; Patent application " a kind of acquisition and purposes that lacks the recombination adenovirus construction body of E1A encoding sequence " (01144628.5) by disappearance E1A (382-1630nt) sequence, filters out the recombination adenovirus construction body that can not express the E1A functional protein; Patent application " a kind of acquisition and purposes of uniting disappearance 19kDa, 55kDa E1B encoding sequence recombination adenovirus construction body " (01144629.3), by uniting disappearance 19kDa, 55kDa E1B encoding sequence, filter out the recombination adenovirus construction body that to express the E1B functional protein.
Domestic and international existing condition replicability adenovirus carrier invention is compared with first-generation ADV5 gene therapy vector, no matter treating on the principle, still on the actual therapeutic effect, all have tangible improvement, and make a breakthrough, be called as s-generation ADV5 gene therapy vector.Yet, s-generation ADV5 gene therapy vector all has some common shortcomings: (1) is though possess the treatment advantage of tumour condition replicability based on the carrier of adenovirus Basic of Biology design, because all deficiencies in the design, the effectiveness of the adenovirus of obtaining duplicating in tumour cell, cracking tumour cell is weaker than wild-type ADV5 far away, as single only be 0-14% with the anticancer efficient of ONYX-015.(2) application of s-generation ADV5 gene therapy vector is still based on locally injected into tumor, in application, be subjected to great restriction, under most situations, tumour is a kind of systemic disease, needs the approach through intravenous administration, carries out systemic treatment, to control former and metastatic lesion, therefore, the selectivity of s-generation ADV5 gene therapy vector and must further strengthen the killing-efficiency of tumour cell is to adapt to the needs that improve route of administration.(3) s-generation ADV5 gene therapy vector does not all carry effective therapeutic goal gene, and the performance of treatment effect is restricted.(4) because the existing molecular target overwhelming majority lacks tumour-specific, though have relative tumor-selective with s-generation ADV5 gene therapy vector in conjunction with the strategy of exogenous promotor, therapeutic gene, but still can not avoid to normal histiocytic toxic action.
In addition, many tumour molecule medicine targets have been determined in recent years, at these molecule medicine target design monoclonal antibodies, micromolecular compound, become the oncotherapy main development tendency, wherein, part has become prescription drugs, a large amount of molecular therapy means is still arranged just in clinic trial evaluation stage, and has obtained PRELIMINARY RESULTS preferably.However, because these new molecular targets and molecule thereof check means, the overwhelming majority lacks tumour-specific, consequent dose-limiting toxicity, remain the key issue that these therapies generally face and need to be resolved hurrily at present, greatly limited the solution of tumour problem.
Three, summary of the invention
Based on above technical background and great medical requirement, the present invention will disclose a kind of constructing plan of third generation ADV5 gene therapy vector, the construct that obtains by this scheme has remarkable advantages such as tumour-specific duplicates, the exogenous insertion inverted defined gene of tumor specific expression, tumour-specific bystander effect, and possess the height therapeutic index, be suitable for intravenous administration, can solve crucial weak point in present oncotherapy technology and the practice.
Theoretical basis of the present invention deeply is familiar with and research the ADV5 adenovirus is biological based on existing.After ADV5 enters cell in 1 hour, ADV5 will give expression to the E1A functional protein, its biological effect mainly comprises two aspects: at first, E1A protein binding retinoblastoma mutator gene (Rb) albumen, host cell endogenous transcription factor E2F is discharged from the mixture of Rb-E2F, meanwhile, E1A albumen will activate ADV5 and give expression to the E1B functional protein, drive kinase whose inhibition with this deactivation host cell endogenous transcription factor P53 cell cycle, at E1A, under the common driving of E1B and E2F, host cell enters the DNA synthesis phase, for the self-replacation of adenoviral gene group provides precondition; Secondly, ADV5 relies on the early gene (E1B that E1A albumen activates ADV5, E2, E3, E4) and the expression of late gene (L1-6), for the self-replacation of adenoviral gene group, the packing of adenovirus particles, the immune clearance of escaping host cell, lysing cell, release adenovirus particles, complete life cycle such as infection provides the permission environment again.This shows that ADV5 relies on the life cycle of its sequential property of E1A protein promoter, final cracking host cell.
The encoding sequence of functional protein E1A is positioned at ADV5 genome 560-1112nt, and 1229-1545nt comprises three important sequences: be respectively 677-799nt, this sequence is E1A conserved sequence 1 (CR1), is used in conjunction with transcribing cofactor P
300917-979nt is E1A conserved sequence 2 (CR2), is used in conjunction with retinoblastoma mutator gene (Rb); 1007-1115nt is conserved sequence 3 (CR3), is the genetic transcription active region.Because all there is the defective of Rb regulation and control pathway in nearly all tumour, if the disappearance transformation different in addition to the CR2 district of E1A 917-979nt, reach the effect that in the proteic RB binding characteristic of deactivation E1A, keeps the E1A transcripting activating characteristic as far as possible, so, the adenovirus recombinant chou that obtains thus might effectively duplicate in tumour cell, finally kill tumour cell; On the other hand, the Rb regulation and control pathway that normal cell has can effectively be checked the life cycle that the adenovirus recombinant chou relies on its sequential property of E1A protein promoter, finally only forms abortive infection.This is theoretical infer by recent two independently the work of study group confirmed, (Oncogene such as Fueyo, 2000,19:2-12) made up the adenovirus recombinant chou that lacks E1A 923-946nt, observing this adenovirus recombinant chou optionally duplicates in tumour cell, and normal cell is not had any toxic action, list can significantly suppress tumor growth with this adenovirus recombinant chou; Heise etc. (NatureMedicine, 2000,10:1134-1139) confirm that more in depth this construct has high selectivity to tumour cell, list can significantly suppress tumor growth and suppress metastases with this adenovirus recombinant chou.
Although the previous work of Fueyo and Heise etc. provides crucial theoretical clue for development third generation ADV5 gene therapy vector, their work still has tangible weak point, preferred plan to the disappearance transformation of E1A 917-979nt district, the effect that should keep the E1A transcripting activating characteristic on the theoretical and actual effect in the proteic RB binding characteristic of deactivation E1A as far as possible, the previous work of Fueyo and Heise etc. be result of lacking of other E1A 917-979nt districts without comparison to this; The most key is that they develop the ADV5 gene therapy vector that and do not comprise the exogenous therapeutic gene of any insertion, have limited the performance of anti-tumour effect.For this reason, the present invention will make up a kind of novel ADV5 recombinant chou, its technical characterictic is: the genomic 923-931nt sequence of directed disappearance ADV5 (CTT ACC TGC, this sequence encoding E1A protein 12 2 to 124 amino acids), on this basis, further disappearance ADV5 E3 district 28532-29360nt introduces a ClaI restriction enzyme site in this disappearance zone; In the ClaI restriction enzyme site, oppositely insert the exogenous PLK1cDNA fragment (960-161nt that is equivalent to PLK1mRNA) of 820bp, thereby obtain the recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 that tumour is had therapeutic action.
PLK1 gene full name polo-like kinase 1, the key that is the cell mitogen check point is regulated kinases, its function is to promote cell to enter and finish mitotic division, in most of tumour cell unconventionality expression is arranged, and it is relevant with the genomic instability of tumour cell, existing ample evidence show PLK1 be cell necessity lifetime because of, and therefore deactivation PLK1, is chosen as molecule medicine target in the present invention with direct cell death inducing.
Compare with existing recombination adenovirus construction body, the present invention has reached following effect:
1, the proteic 923-931nt sequence of this recombination adenovirus construction body disappearance E1A, range of loss is less than the construct of report such as Fueyo and Heise, theoretical and in fact reached the effect that keeps the E1A transcripting activating characteristic in the proteic RB binding characteristic of deactivation E1A as far as possible.What is more important, we oppositely insert the exogenous PLK1cDNA fragment (960-161nt that is equivalent to PLK1mRNA) of 820bp in the E3 6.7K/gp19K district of Δ 923-931ADV5 carrier, make the endogenous promotor of expression dependence ADV5 self the E3 district transcription unit of antisense PLK1cDNA, this promotor has the high reactivity of similar CMV promotor, the opening of the promotor adenovirus that places one's entire reliance upon is duplicated intracellular, adenovirus is not as duplicating, and exogenous antisense PLK1cDNA will not express.Because this brand-new design makes this new construct can reach the therapeutic purpose of selectively killing tumour cell by triple mechanism, that is: construct duplicating in tumour cell can make exogenous antisense PLK1cDNA copy number greatly increase; Construct carries antisense PLK1cDNA and only expresses in tumour cell, and the PLK1 genetic expression of specifically inactivating tumour cell reaches the purpose of killing tumour cell, has avoided Normocellular attack; Construct for duplicating the host, can produce high density adenovirus at tumor by local with tumour cell, forms potent bystander effect.In addition, the present invention also will provide a kind of Design Mode of use for follow-up other molecular therapies.
2, the antitumour drug such as the vincristine(VCR) of existing multiple effect m period, nvelbine, taxols etc. all are action target spot with the spindle microtubule, lack selectivity, be difficult to avoid toxicity, side effect strong, the little shortcoming of treatment window has limited the performance of clinical efficacy between host and the tumour, the present invention adopts more specific m period molecular target PLK1, is a kind of antitumour drug of brand-new effect m period.
3, tumor cell line and normal control cells in vitro experimental result are shown, this recombination adenovirus construction body does not have obvious influence to normal cell PLK1 expression of gene, and the obviously influence of the active nothing of pair cell is opposite, but its specifically inactivating PLK1 expression of gene is killed tumour cell significantly.
4, the body inner model to animal model for tumour studies confirm that, by locally injected into tumor or intravenous route of administration, all animal models for tumour equal tool significant therapeutic action of this recombination adenovirus construction body to being tried, and can effectively suppress metastases, and it is xicity related that animal is not had obvious treatment.
Four, description of drawings:
Accompanying drawing 1: the structural representation of plasmid pXC1, this plasmid comprise human 5 type adenovirus (ADV5) 21-5790nt sequences.
Accompanying drawing 2: the structural representation of plasmid pBHGE3, this plasmid comprise the full gene group sequence except that ADV5 packaging signal (194-358nt), and insert one section artificial sequence between 194-358nt, total length 37436bp.
Accompanying drawing 3:ADV5E3 plot structure figure, 7 kinds of albumen of this regional code, the zone that lack is 28530-29355bp, is E36.7k/gp 19k zone, oppositely inserts the exogenous PLK1cDNA fragment (960-161nt that is equivalent to PLK1mRNA) of 820bp in this zone.
The plasmid structure iron of accompanying drawing 4:pCDNA3.1, this carrier are used to make up intermediate carrier pCDNA3.1-Δ E3.
Accompanying drawing 5: the sequence of recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 and structure explanation.
Five, embodiment
Except that indicating especially, used enzyme and PCR primer are all available from U.S. Gibco company in the present technique flow process.
The structure of embodiment 1:pXC1 series mutation body Δ 923-931pXC1
1, pXC1 purchases the (Toronato in Microbix Biosystem Inc., Ontario, Canada, catalog number (Cat.No.): PD-01-03), this plasmid comprises human 5 type adenovirus (ADV5) 21-5790nt sequences, its plasmid structure iron is seen accompanying drawing 1, the 194-358nt of this plasmid is an ADV5 adenovirus packaging signal, and sequence 560-1112nt, 1229-1545nt are the encoding sequence of functional protein E1A, 9883-9888nt comprises the BamHI restriction enzyme site, and 1338-1343nt comprises the XbaI enzyme cutting site.
2, adopt PCR method disappearance 923-931nt 3 times.
(1) obtaining of fragment 1: primer 1=5 '-CG
GGA TCCGGG CCC CCA TTT CC-3 ' (is equivalent to 9883-9902nt; Underscore partly is the BamHI restriction enzyme site); Primer 2=5 '-
GTCACTGGGTGGGATCAC CTC CGGTAC AAG-3 ' (is equivalent to 922-905nt; Underscore partly is and primer 3 complementary portions).
With pXC1 is template, the performing PCR reaction, and the reaction system cumulative volume is 100 μ l, comprising: contain MgCl
210 * PCR damping fluid, 10 μ l; 2mM dNTP 10 μ l; 10 μ M primers, 11 μ l; 10 μ M primer 2s, 1 μ l; PXC1 10ng/1 μ l; Pfu high-fidelity Taq enzyme 2.5u; Add water to 100 μ l.
Reaction conditions is: 95 ℃ 30 seconds; 95 ℃ 45 seconds, 60 ℃ 1 minute, 72 ℃ totally 28 circulations in 2 minutes; 72 ℃ were extended 10 minutes.The PCR product is 940bp (fragment 1), and behind the conventional electrophoretic separation purifying, detectable level is used for follow-up PCR reaction.
(2) obtaining of fragment 2: primer 3=5 '-
CCG GAG GTG ATC CCA CCC AGT GACGACGAG-3 ' (is equivalent to 908-964nt; Underscore partly is and the primer 2 complementary portion); Primer 4=5 '-TGC
TCT AGACAC AGG TGA TGT CG-3 ' (is equivalent to 1344-1325nt; Underscore partly is the XbaI enzyme cutting site).With pXC1 is template, the performing PCR reaction, and reaction conditions is the same, and product is 400bp (fragment 2), and behind the conventional electrophoretic separation purifying, detectable level is used for follow-up PCR reaction.
(3) obtaining of fragment 3: 50ng/2 μ l fragment 1 is mixed with 25ng/1 μ l fragment 2, as the reaction of template performing PCR, upstream primer is a primer 1, and downstream primer is a primer 4, reaction conditions is the same, product is about 1400bp (fragment 3), with QIAquick 8PCR product purification test kit (QIAGEN, German, Cat:28142) behind the purifying, use BamHI, the XbaI double digestion spends the night, and enzyme is cut product recovery endonuclease bamhi after 1% agarose gel electrophoresis separates and is used for the clone.
3, with pXC1 BamHI, the XbaI double digestion spends the night, and enzyme is cut product and separated back generation 2 bands at 1% agarose gel electrophoresis, is about 1400bp and 8200bp, reclaims the 8200bp endonuclease bamhi and is used for the clone.Get 8200bp pXC1 endonuclease bamhi and the 90ng fragment 3 of 40ng, do ligation with DNA T4 ligase enzyme, get 1.5 μ l and change 100 μ l DH5 α competence bacteriums over to, the picking positive colony, plasmid is carried for a short time, the dna sequencing evaluation and screening obtains lacking pXC1 plasmid encoding mutant body-Δ 923-931pXC1 of 121-129AA 923-931nt, is used for the clone of recombinant adenovirus.
Embodiment 2: the structure of Δ 923-931ADV5 recombinant adenovirus
1, pBHGE3 purchases the (Toronato in Microbix Biosystem Inc., Ontario, Canada, catalog number (Cat.No.): PD-01-12), this plasmid comprises the full gene group sequence except that ADV5 packaging signal (194-358nt), and between 194-358nt, insert one section artificial sequence, and total length 37436bp, its structure is seen accompanying drawing 2.
When pBHGE3 obtained from Microbix Biosystem Inc., total amount was 10 μ g, and first electricity changes the competence bacterium over to, and the picking positive colony because the plasmid fragment is very long, need be used CsCl
2-Eb ultracentrifugation plasmid purification is undertaken by the method for " molecular cloning " book.
2, homologous recombination method obtains Δ 923-931ADV5 recombination adenovirus construction body, and method is as follows:
(1) in the 15cm culture dish, plants 7.5 * 10
5(catalog number (Cat.No.): CRL-1573), nutrient solution is 10%FBS DMEM to 293 cells, and by second day, cell should be 1-1.5 * 10 for ATCC, U.S.A
6, about 70% cytogamy; Preceding 3-4 hour of transfection changes fresh medium into.
(2) preparation cotransfection DNA-calcium phosphate solution: with 2 * HBS (280mM NaCl, 43mM HEPES, 10mM KCl, the 10mM Na of 1600 μ l sterilization
2HPO
4.7H
2O, 2%dextrose, pH7.05-7.15); Each 42 μ g of pBHGE3 and Δ 923-931pXC1; Distilled water to the 2840 μ l mixing that adds sterilization slowly adds the CaCl of 50 μ l 2.5M
2, put upside down mixing, at room temperature allow DNA/CaCl
2Precipitate 45-60 minute, form slightly turbid precipitation.
(3) add the above-mentioned mixed solution of 500 μ l to 293 cells that contain 5ml 60mm culture dish,, hatched among the 5%CO2 4-6 hour, inhale and remove aforesaid liquid, wash once with PBS at 37 ℃.
(4) handle 1-2 minute to promote transfection efficiency with the glycerine/DMEM that contains 15%, wash once, be changed to complete culture solution with PBS.
(5) preparation 10% LMP agarose PBS, autoclaving is distributed into 10ml, melts in boiling water with preceding, and insulation is at 45 ℃, and with preceding adding 30ml 10%FBS DMEM, final concentration is 1.2%, at once use.
(6) nutrient solution is removed in suction, adds the 5ml aforesaid liquid.Every 4-5 days, add the 3ml aforesaid liquid.
(7) 14-21 days, plaque occurred, and selected 6-12 plaque with mark stroke circle, with the suction nozzle of 200 μ l, transferred to plaque 24 orifice plates of the 0.5ml that contains 10%FBS DMEM, filters 24 hours in 37 ℃.
(8) in 24 orifice plate culture dish, plant 1 * 10
5293 cells, nutrient solution are 10%FBS DMEM, and by second day, cell should be 2 * 10
5, about 70% cytogamy is inhaled and is removed liquid, gets 100 μ l from above-mentioned filtered solution and (is approximately 10
3Adenovirus) adds, rock liquid gently 3 times, at 37 ℃, 5%CO
2In hatched 90 minutes.
(9) add perfect medium to 1ml, cell is positioned in 37 ℃, 5%CO2 hatched 5-10 days, occur until CPE completely, so-called CPE, i.e. cellulotoxic effect, cell shows as and becomes circle, and floating, cell is based on kernel.If after 10 days, CPE does not occur completely, then point out tiring of adenovirus too low, need carry out second amplification of taking turns.
(10) culture plate is carried out the circulation of freezing or thawing of three-wheel, discharge adenovirus, lysate is collected in the 15ml test tube, maximum velocity centrifugation 10 minutes is collected supernatant liquor, freezes in-80 ℃, and this liquid is called s-generation adenovirus, is approximately 5 * 10
7/ ml adenovirus.
(11) above adenovirus is increased once more, at 75cm
2Plant 5 * 10 in the culture dish
6293 cells, nutrient solution are 10ml 10%FBS DMEM, and by second day, cell should be 1 * 10
7, about 70% cytogamy; Preceding 3-4 hour of transfection changes fresh medium into; Get 1ml s-generation adenovirus storage liquid and add perfect medium, be used for transfection to 1ml; This MOI is about 5; Remove 75cm
2The liquid of culture dish adds above liquid, shakes gently three times; In 37 ℃, 5%CO2, hatched 90 minutes; Add 9ml 10%FBSDMEM, in 37 ℃, 5%CO2, hatched 4-7 days, be used to extract the screening that adenovirus DNA is used for positive adenovirus.
(12) because 293 cellular genome comprise complete e1a gene, pollute 293 cell DNAs when extracting positive adenovirus DNA easily, cause and identify failure, for this reason with Δ 923-931ADV5 at tumour cell Hela (ATCC, U.S.A, catalog number (Cat.No.): increase once again CCL-2), be used for identifying that step is as follows:
In 6 orifice plate culture dish, plant 1 * 10
5Hela cell, nutrient solution are 10%FBS DMEM, and by second day, cell should be 2 * 10
5, about 70% cytogamy is inhaled and is removed liquid, gets 100 μ l from above-mentioned filtered solution and (is approximately 10
3Adenovirus) adds, rock liquid gently 3 times, at 37 ℃, 5%CO
2In hatched 90 minutes.
Add perfect medium to 1ml, cell is positioned in 37 ℃, 5%CO2 hatched 5-10 days, occur until CPE completely, cell is scraped, be collected in 1.5ml EP pipe, the centrifugal supernatant of abandoning, add 300 μ lPBS solution, carry out the circulation of freezing or thawing of three-wheel, discharge adenovirus, with lysate maximum velocity centrifugation 10 minutes, collect supernatant liquor, freeze in-80 ℃, with the Qiagen test kit mini DNA isolationkit of company, DNA is extracted in the explanation of reference reagent box.With the adenovirus DNA is template, the performing PCR reaction, upstream primer=5 '-CG GGA TCC GGG CCC CCA TTT CC-3 ', downstream primer=5 '-TGC TCT AGA CACAGG TGA TGT CG-3 ', the reaction system cumulative volume is 100 μ l, comprising: 10 * PCR damping fluid, the 10 μ l that contain MgCl2; 2mM dNTP 10 μ l; 10 μ M upstream primers, 1 μ l; 10 μ M downstream primers, 1 μ l; Adenovirus DNA 10ng; Pfu high-fidelity Taq enzyme 2.5u; Add water to 100 μ l.Reaction conditions is: 95 ℃ 30 seconds; 95 ℃ 45 seconds, 60 ℃ 1 minute, 72 ℃ totally 28 circulations in 2 minutes; 72 ℃ were extended 10 minutes.The PCR product is 1400bp, and behind the conventional electrophoretic separation purifying, detectable level is used for dna sequencing, and sequencing primer is: 5 '-AGCCGGAGCA GAGAGCCTTG-3 ', pick out correct clone and be used to make up Δ 923-931ADV5/ASPLK1 reorganization gland adenovirus.
The structure of the subcloning vector pCDNA3.1-Δ E3 in embodiment 3:ADV5 E3 district
1, ADV5 E3 district full name is an ADV5 early region 3, this zone under the driving of endogenous promotor, the 7 kinds of albumen of encoding, sequence, structure, function following (seeing accompanying drawing 3): 12.5k, 27858-28179nt, function is not bright; 6.7k, 27547-28736nt, function is not bright; Gp19k, 28735-29215nt in conjunction with MHCI class antigen, suppresses it and presents to cell surface, consequently escapes the removing of CTL; ADP, 29419-29770nt, lysing cell discharges adenovirus; RID α, 29784-30057nt forms mixture with RID β, prevents the cracking of TNF, removes FAS antigen; RID β, 30062-30458nt; 14.7k 30453-30837 suppresses the cracking of TNF.
The purpose of this experiment is to lack 28530-29355nt zone, E3 district, and inserts exogenous therapeutic gene in the E36.7k/gp of recombinant adenovirus 19k zone.
2, adopt PCR method disappearance ADV5E3 district 28532-29360nt 3 times.
(1) obtaining of fragment 1: primer 1=5 '-GGG TCA ACG GAA TCC GCG CC-3 ' (being equivalent to 27301-27320nt); Primer 2=5 '-
CCC ACA TAG AGT ATC GATTGC GCC TTTGGC CTA ATA-3 ' (be equivalent to 28531-28514nt, underscore partly is and primer 3 complementary portions that ATC GAT is the ClaI restriction enzyme site).
ADV5 adenovirus genomic dna template derives from wild-type ADV5 (Chengdu this yuan gene therapy company), and the obtaining step of adenovirus DNA is as follows: wild-type ADV5 Adenovirus Transfection 293 cells, and at 75cm
2Inoculate 5 * 10 in the culturing bottle
6293 cells, next day, about 70% cytogamy, cell should be 1 * 10
7Individual; Preceding 3-4 hour of transfection changes fresh medium into, draws 1 μ l wild-type ADV5 adenovirus to be checked, with 1ml DMEM mixing, makes MOI be about 20; Remove 75cm
2The liquid of culturing bottle adds aforesaid liquid, shakes gently three times, at 37 ℃, 5%CO
2In hatched 90 minutes; Add 9ml 10%FBS DMEM, at 37 ℃, 5%CO
2In hatched 72 hours, discard nutrient solution, give a baby a bath on the third day after its birth time with PBS, discard liquid, add the freshly prepared cell pyrolysis liquid of 800 μ l, hatched 1 hour for 37 ℃, the cell mixture after the cracking is added in the eppendorf pipe of 1.5ml, 4 ℃ 12, centrifugal 45 minutes of 000g; Get supernatant, with isopyknic phenol/chloroform extracting once, get supernatant liquid, add the 3M NaAc of 1/10 volume, the dehydrated alcohol of 2 volumes, hatched one hour at-20 ℃, 12, centrifugal 30 minutes of 000g, 70% ethanol is washed once, with the resuspended adenovirus DNA of 25 μ l TE, on spectrophotometer, measure the concentration of DNA, DNA is frozen stand-by in-70 ℃.
With ADV5DNA is template, the performing PCR reaction, and the reaction system cumulative volume is 100 μ l, comprising: contain MgCl
210 * PCR damping fluid, 10 μ l; 2mM dNTP 10 μ l; 10 μ M primers, 11 μ l; 10 μ M primer 2s, 1 μ l; ADV5DNA 200ng/1 μ l; Pfu high-fidelity Taq enzyme 2.5u; Add water to 100 μ l;
Reaction conditions is: 94 ℃ 30 seconds; 94 ℃ 30 seconds, 62 ℃ 1 minute, 72 ℃ totally 28 circulations in 1 minute; 72 ℃ were extended 10 minutes.
The PCR product is 1200bp (fragment 1), and behind the conventional electrophoretic separation purifying, detectable level is used for follow-up PCR reaction.
(2) obtaining of fragment 2: primer 3=5 '-
GCC AAA GGC GCA ATC GATACT CTA TGTGGG ATA TGC TCC AG-3 ' (be equivalent to 29361-29383n, underscore partly is and the primer 2 complementary portion that ATC GAT is a Cla I restriction enzyme site).Primer 4=5 '-GGG GAA CAA AAC GCA GATAGG-3 ' (being equivalent to 30090-30120nt); The PCR reaction conditions is the same, and product is 780bp (fragment 2), and behind the conventional electrophoretic separation purifying, detectable level is used for follow-up PCR reaction.
(3) obtaining of fragment 3: 50ng/2 μ l fragment 1 is mixed with 25ng/1 μ l fragment 2, as the reaction of template performing PCR, upstream primer is a primer 1, and downstream primer is a primer 4, reaction conditions is the same, product is about 2200bp (fragment 3), with QIAquick 8PCR product purification test kit (QIAGEN, German, Cat:28142) behind the purifying, cut with the EcoRI enzyme and to spend the night, enzyme is cut product and is separated the back at 1% agarose gel electrophoresis and reclaim, and endonuclease bamhi is used for follow-up ligation.
3, (Invitrogen, U.S.A. Cat:V79020) cut with the EcoRI enzyme and spend the night, and enzyme is cut product and separated the back at 1% agarose gel electrophoresis and reclaim endonuclease bamhi, is used for follow-up ligation behind the dephosphorylation, and the structure of pCDNA3.1 is seen accompanying drawing 4 with pCDNA3.1.
4, PCR reaction product fragment 3 and enzyme are cut, pCDNA3.1 connects behind the dephosphorylation, get 1.5 μ l and change 100 μ l DH5 α competence bacteriums over to, the picking positive colony, plasmid is carried for a short time, the dna sequencing evaluation and screening obtains lacking pCDNA3.1 plasmid encoding mutant body-pCDNA3.1-Δ E3 of 28532-29360nt, is used to insert the subclone of exogenous therapeutic gene.
Embodiment 4: the exogenous PLK1cDNA fragment of oppositely inserting 820bp in carrier pCDNA3.1-Δ E3
1, the PLK1cDNA fragment is HL-60 (ATCC from the leukemia cell, U.S.A, catalog number (Cat.No.): amplification among RNA CCL-240), RNA extracts and adopts RNA to extract test kit RNeasy Mini Kit (QIAGEN, GERMAN, catalog number (Cat.No.): 74104), concrete steps are carried out with reference to the test kit specification sheets that the manufacturer provides.
2, reverse transcription condition: 5 * MMLV damping fluid, 4 μ l; 10mMdNTP 1 μ l; OligdT (50ng/ml) 1 μ l; Total RNA 2 μ l; Rnasin 0.5 μ l; MMLV reversed transcriptive enzyme 1 μ l; Add no RNA enzyme water to 20 μ l.
The reverse transcription reaction product is used for the PCR reaction.Upstream primer is 5 '-CC
ATC GATGGC TCC ACC GGCGAA AGA GA-3 ' (161-180nt that is equivalent to PLK1 cDNA encoding sequence, underscore partly are the ClaI restriction enzyme site); Downstream primer is 5 '-CC
ATC GATGCA GCT CGT TAA TGG TTG GG-3 ' (960-941nt that is equivalent to the PLK1cDNA encoding sequence, underscore partly are the ClaI restriction enzyme site), amplified fragments comprises the 960-161nt of PLK1cDNA encoding sequence, total length is about 820bp.
The reaction system cumulative volume is 100 μ l, comprising: contain MgCl
210 * PCR damping fluid, 10 μ l; 2mM dNTP 10 μ l; 10 μ M upstream primers, 1 μ l; 10 μ M downstream primers, 1 μ l; Reverse transcription reaction product 2 μ l; Pfu high-fidelity Taq enzyme 2.5u; Add water to 100 μ l;
Reaction conditions is: 94 ℃ 30 seconds; 94 ℃ 30 seconds, 62 ℃ 1 minute, 72 ℃ totally 30 circulations in 1 minute; 72 ℃ were extended 7 minutes.The PCR product is 820bp, and after the ClaI enzyme was cut, conventional electrophoretic separation purifying, detectable level were used for follow-up PCR reaction.
3, after carrier pCDNA3.1-Δ E3 uses ClaI enzyme tangent line shapeization, conventional electrophoretic separation purifying, be connected with the exogenous PLK1cDNA fragment of 820bp behind the dephosphorylation, get 1.5 μ l and change 100 μ l DH5 α competence bacteriums over to, the picking positive colony, plasmid is carried for a short time, and the dna sequencing evaluation and screening obtains oppositely inserting at the ClaI restriction enzyme site the segmental plasmid encoding mutant body of exogenous PLK1cDNA-pCDNA3.1-Δ E3/ASPLK1 of 820bp, is used for the clone of follow-up recombinant adenovirus.
Embodiment 5: recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 obtains
Recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 obtains according to reference " Adenovirus methods and protocol " (edited by William S.M.Wold, construction of mutations in the adenovirus early region 3＜E3〉transcription units, 11-24) connection method of Jian Liing (ligation protocol) is carried out, and key step is as follows:
1, the extraction of TP DNA
(1), gets recombination adenovirus construction body Δ 923-931ADV52 * 10
8, be dissolved in 10ml DMEM, make MOI be about 10; 75cm one bottle of 80-90% fusion
2The culture dish kind is gone into 293 cells, and this moment, cell was about 2 * 10
7Cell adds the above liquid of 1ml, shakes gently three times, at 37 ℃, 5%CO
2In hatched 90 minutes, add 10%FBS DMEM to total amount of liquid be 10ml, at 37 ℃, 5%CO
2In hatched 4-5 days, obtain 2 * 10
10Adenovirus, centrifugal, supernatant discarded adds 10ml 10%FBS DMEM, carries out the circulation of freezing or thawing of three-wheel, discharges adenovirus, and concentration is 2 * 10
9/ ml, with lysate with the volume packing of 1ml frozen be 10 the pipe.Amplification for the second time: before the transfection, get the above-mentioned frozen storing liquid of 1 pipe and add 9ml DMEM, concentration is 2 * 10
9/ ml, transfection 10 * 75cm
2The cell of culture dish is at the 75cm of ten bottles of 80-90% fusions
2Culture dish 293 cells respectively are 2 * 10 approximately
7Cell, each adds the above liquid of 1ml, shakes gently three times, at 37 ℃, 5%CO
2In hatched 90 minutes, add 10%FBS DMEM to total amount of liquid be 10ml, at 37 ℃, 5%CO
2In hatch 4-5 days, centrifugal, supernatant discarded repeats above transfection ten times, obtains altogether 2 * 10
13Adenovirus, frozen in-80 ℃, preserve to be purified.
(2), the collection of 293 cells, concentrated and frozen: with 30ml PBS resuspending cell precipitation, cell suspension is merged the centrifuge tube that places 2 50ml, at liquid nitrogen or ethanol, alternate freezing and thawing is three times in 37 ℃ of water-baths, make cell rupture, dissolving, discharge Δ 923-931ADV5, centrifugal 5 minutes of 2500rpm is to remove cell debris on generic centrifuge, the centrifuging and taking supernatant freezes in-70 ℃ to be purified.
(3) separation and purification of Δ 923-931ADV5: Δ 923-931ADV5 adopts cesium chloride density gradient centrifugation to carry out purifying, can obtain the adenovirus of extreme high purity.
Supernatant is placed CsCl
2In the liquid (Gibco, U.S.A, catalog number (Cat.No.): 456-32), and on two SW-40TL rotors centrifugal 4 ℃, 35,000rpm (150,000 * g), 1 hour.
The preparation of CsCl2 gradient centrifugation liquid:
A:1.5gm/ml CsCl
2Gradient centrifugation liquid, 30g CsCl
2, being dissolved among the PBS, its final volume is 42.5ml.
B:1.35gm/ml CsCl
2Gradient centrifugation liquid is got 15ml A liquid, adds PBS 7ml, and its final volume is 21ml.
C:1.25gm/ml CsCl
2Gradient centrifugation liquid is got 11ml A liquid, adds PBS 9ml, and its final volume is 20ml.
Filtration sterilization accurately takes by weighing the liquid weight of each pipe after degerming, and carries out the adjustment of proportion where necessary.
The preparation of gradient centrifugation pipe: the solution of above-mentioned preparation is added in the 12 volumetrical centrifuge tubes in the following manner, and the volume of its adding and order are as follows: 0.5ml 1.5gm/ml CsCl
2Gradient centrifugation liquid; 3.0ml1.35gm/ml CsCl
2Gradient centrifugation liquid; 3.0ml 1.25gm/ml CsCl
2Gradient centrifugation liquid.
After gradient forms, add 6ml cell pyrolysis liquid supernatant, with the weight of each pipe of PBS balance at each pipe.
After centrifugal, adenovirus will be taken present 1.35gm/ml CsCl out of with one deck white area
2Gradient centrifugation liquid and 1.25gm/ml CsCl
2Between the gradient centrifugation liquid.By suction sucking-off upper strata protein, with the careful sucking-off of Pasteur's moral suction pipe middle level gland-containing virus part, in aseptic 100ml centrifuge tube of its income.
With the centrifugal adenovirus solution that obtains for the first time with 1.35gm/ml CsCl
2Gradient centrifugation liquid is diluted to 72ml, and it is dispensed in 6 aseptic centrifuge tubes, after the counterweight, carries out single gradient centrifugation with above-mentioned condition, and centrifugation time extends to 18 hours.
After above-mentioned centrifugal spending the night, Δ 923-931ADV5 adenovirus will form one deck white area band once more.By suction sucking-off upper strata protein, with the careful sucking-off of Pasteur's moral suction pipe middle level gland-containing virus part, in aseptic 100ml centrifuge tube of its income, its harvest yield is approximately 15ml.
(4), dialysis method is removed residual cesium chloride and other small-molecule substances: residual cesium chloride and the small molecular weight impurity in the extract removed in dialysis.Dialyzate: 10mmol Tris-HCl pH7.5; 1mmol MgCl
2Dialysis volume 1000ml * 3 times.
Dialysis process: bar magnet is added in the dialyzate, put 4 ℃ of precoolings, stir dialysis then.It is standby to prepare 100 * Tris-HCl/MgCl2 storage liquid, faces with before being diluted to 1 * dialyzate.Centrifugal product before dialysis earlier the dialyzate with equivalent diluted rearmounted dialysis tubing, in order to avoid precipitate because of adenovirus excessive concentration dialysis back produces.The dialysis tubing that is used to dialyse is facing with preceding with deionized water immersion 30 minutes, and then with the sterilization distilled water wash, clamp the end opening of dialysis tubing, dialysis tubing is placed 1 liter of diluent, seal the dialysis bottle bottleneck with tinfoil paper, in case the direct sunshine photograph is placed on the magnetic stirring apparatus and stirs dialysed overnight at 4 ℃, similarity condition repeats above dialysis 2 times.The gained adenovirus is purification of adenoviral.
(5), column chromatography purification Δ 923-931ADV5 adenovirus TP DNA:
The column chromatography instrument (Hubei Province's scientific instrument company, catalog number (Cat.No.): SSM-213) go up to prepare 250ml Sepharose 4B (Sigma, U.S.A, catalog number (Cat.No.): 4B-200) chromatography column, put 4 ℃, regulate flow velocity to 18ml/h; In the adenopathy venom, add isopyknic proteinase inhibitor pefabloc (Boehringger Mannheim that contains 2mmol/L, catalog number (Cat.No.): 8M hydrochloric acid guanidinium isothiocyanate (Sigma 1 429 876), U.S.A, catalog number (Cat.No.): G9284), after putting on ice 10min, be splined on chromatography column, according to the ratio of absorbance A 260/280, collect TP-DNA (A260/280=1.8-2.0), detect be kept at after the DNA concentration 4 ℃ standby.
2, ligation
PCDNA3.1-Δ E3/ASPLK1 plasmid is cut with the EcoRI enzyme, obtains 10 μ g and comprises the insertion dna fragmentation at interior EcoRI endonuclease bamhi, and dephosphorylation reaction back endonuclease bamhi separates the back recovery at 1% agarose gel electrophoresis, is used for ligation;
After 2.5 μ g Δ 923-931ADV5TP DNA cuts with the EcoRI enzyme, add 5 μ g and comprise the insertion dna fragmentation at interior EcoRI endonuclease bamhi and 10U T4 ligase enzyme, under 16 ℃ of conditions, conventional ligation.
3, connect product cotransfection 293 cells
In the 60mm culture dish, plant 5 * 10
5293 cells, nutrient solution are 10%FBS DMEM, and by second day, cell should be 1 * 10
6, about 70% cytogamy; Preceding 3-4 hour of transfection changes fresh medium into.
To connect product and mix, add aqua sterilisa, add 2.5M 50 μ l CaCl to cumulative volume 450 μ l with 20 μ g salmon sperm dnas
22 * HBS (280mM NaCl, 43mM HEPES, 10mM KCl, 10mM Na in 500 μ l sterilization
2HPO
4.7H
2O, 2%dextrose slowly adds DNA/CaCl in pH7.05-7.15)
2, precipitate 45-60 minute, form slightly turbid precipitation.
Add the above-mentioned mixed solution of 500 μ l to 293 cells of 60mm culture dish, in 37 ℃, 5%CO2, hatched 1/2 hour, inhale and remove aforesaid liquid, wash once with PBS.
Handle 1-2 minute to promote transfection efficiency with the glycerine/DMEM that contains 15%, wash once, be changed to complete culture solution with PBS.
Prepare 10% LMP agarose PBS, autoclaving is distributed into 10ml, melts in boiling water with preceding, and insulation is at 45 ℃, and with preceding adding 30ml 10%FBS DMEM, final concentration is 1.2%, at once use.
Nutrient solution is removed in suction, adds the 5ml aforesaid liquid.Every 4-5 days, add the 3ml aforesaid liquid.
14-21 days, plaque occurred, and selected 6-12 plaque with mark stroke circle, with the suction nozzle of 200 μ l, transferred to plaque 24 orifice plates of the 0.5ml that contains 10%FBS DMEM, filters 24 hours in 37 ℃.
In 24 orifice plate culture dish, plant 1 * 10
5293 cells, nutrient solution are 10%FBS DMEM, and by second day, cell should be 2 * 10
5, about 70% cytogamy is inhaled and is removed liquid, gets 100 μ l from above-mentioned filtered solution and (is approximately 10
3Adenovirus) adds, rock liquid gently 3 times, at 37 ℃, 5%CO
2In hatched 90 minutes.
4, the picking of plaque and evaluation
Obtain recombination adenovirus construction body by above experimental procedure, rotaring redyeing 293 cell again, extract adenovirus DNA, Δ 923-931ADV5/ASPLK1 is identified in order-checking, positive adenovirus should lack ADV5923-931nt sequence (CTT ACC TGC), and disappearance ADV5E3 district 28532-29360nt, comprises exogenous PLK1cDNA fragment (960-161nt that is equivalent to PLK1mRNA) in this zone, other genome structures and wild-type ADV5 are identical, and its sequence and structure are seen accompanying drawing 5.
Embodiment 6: recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 characterized
1, the external tumour-specific of the recombination adenovirus construction body evaluation of duplicating
The purpose of this experiment is to identify the duplicate characteristics of Δ 923-931ADV5/ASPLK1 recombinant adenovirus in a series of tumours and normal cell, experiment will be with the positive contrast of wild-type ADV5, with the negative contrast of ADV-TK (being the replication-defective adenoviral that this study group makes up voluntarily).Selecting cell for use is that (catalog number (Cat.No.): CCL-185), Hela, human osteoblast cell's oncocyte are U-20S (P53+, RB-to A549 for ATCC, U.S.A; ATCC, U.S.A, catalog number (Cat.No.): HTB-96), the metastatic human adenoma cell is HS700T (P53-, RB-; ATCC, U.S.A, catalog number (Cat.No.): HTB-147), CCL188 DLD-1 (P53-, RB-; ATCC, U.S.A, catalog number (Cat.No.): CCL-221), MCF-7 (P53+, RB+; ATCC, U.S.A, catalog number (Cat.No.): HTB-22).The clone of selecting for use has different P53, RB gene phenotype; Have different tissues-derivedly, so experimental result can be represented different types of tumors.The normal cell of selecting for use is lung tracheole epithelial cell, prostate epithelial cell, the BMNC in the vascular endothelial cell in former generation, former generation, these normal cells separate from clinical samples and obtain, and select for use principle to be: the normal tissue cell that will contact a large amount of adenovirus after the intravenous administration.
In 24 orifice plate culture dish, plant 1 * 10
5Tumour or normal bone marrow mononuclearcell (derive from clinical offer the marrow voluntarily person), nutrient solution is 10%FBS DMEM, by second day, cell should be 2 * 10
5, about 70% cytogamy is inhaled and is removed liquid, and adding reaches 70% required MOI and is diluted to 100 μ l adding, rocks liquid gently 3 times, at 37 ℃, 5%CO
2In hatched 90 minutes.
Add and to contain 1%FBS DMEM substratum to 1ml, cell is positioned in 37 ℃, 5%CO2 hatched 3-10 days, the required time of complete CPE appears in observation of cell.
Experimental result shows, positive control adenovirus wild-type adenovirus hominis 5 non-selectivities ground cracking tumour and normal cell; Replication-defective adenoviral (ADV-TK) can not any cell of cracking, recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 is the cracking tumour cell optionally, its effect significantly is better than wild-type adenovirus hominis 5, and this recombination adenovirus construction body is to the obviously influence of normal control cells system's nothing simultaneously.The result fully shows recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 selectively killing tumour cell, and concrete data see the following form:
| Wild-type ADV5 | ADV-TK | Δ923-931ADV5/ ASPLK1 | |
| A549 | |||
| The 3rd day | 50％ | 1％ | 95％ |
| The 6th day | 100％ | 2％ | 100％ |
| The 10th day | 4％ | ||
| Hela | |||
| The 3rd day | 60％ | 1％ | 90％ |
| The 6th day | 100％ | 2％ | 100％ |
| The 10th day | 4％ | ||
| U-20S | |||
| The 3rd day | 60％ | 1％ | 90％ |
| The 6th day | 100％ | 2％ | 100％ |
| The 10th day | 4％ | ||
| HS700T | |||
| The 3rd day | 60％ | 1％ | 90％ |
| The 6th day | 100％ | 2％ | 100％ |
| The 10th day | 4％ | ||
| DLD-1 | |||
| The 3rd day | 60％ | 1％ | 90％ |
| The 6th day | 100％ | 2％ | 100％ |
| The 10th day | 4％ | ||
| MCF-7 | |||
| The 3rd day | 60％ | 1％ | 92％ |
| The 6th day | 100％ | 1％ | 100％ |
| The 10th day | 1％ | ||
| Vascular endothelial cell | |||
| The 3rd day | 60％ | 1％ | 4％ |
| The 6th day | 100％ | 2％ | 4％ |
| The 10th day | 4％ | 4％ | |
| Lung tracheole epithelial cell | |||
| The 3rd day | 60％ | 1％ | 3％ |
| The 6th day | 100％ | 2％ | 3％ |
| The 10th day | 4％ | 6％ | |
| Prostate epithelial cell | |||
| The 3rd day | 60％ | 1％ | 4％ |
| The 6th day | 100％ | 2％ | 4％ |
| The 10th day | 4％ | 5％ | |
| BMNC | |||
| The 3rd day | 60％ | 1％ | 2％ |
| The 6th day | 100％ | 2％ | 2％ |
| The 10th day | 4％ | 6％ |
For further carrying out detection by quantitative Δ 923-931ADV5/ASPLK1 recombination adenovirus construction body duplicating efficiency in tumour cell, carried out following experiment:
Variously in 24 orifice plate culture dish go into 1 * 10
5Various tumour cells or former generation normal cell, nutrient solution is 10%FBS DMEM, by second day, cell should be 2 * 10
5, about 70% cytogamy is inhaled and is removed liquid, adds Δ 923-931ADV5/ASPLK1 10MOI and is diluted to 100 μ l adding, rocks liquid gently 3 times, at 37 ℃, 5%CO
2In hatched 90 minutes.
Add and to contain 1%FBS DMEM substratum, cell is positioned in 37 ℃, 5%CO2 hatched 6 days to 1ml.
Add 300 μ l PBS solution, carry out the circulation of freezing/thawing of three-wheel, discharge adenovirus,, collect supernatant liquor, freeze, use TGID in-80 ℃ with lysate maximum velocity centrifugation 10 minutes
50In 293 cells, detect the titre of adenovirus.
The result shows and duplicates the back by Δ 923-931ADV5/ASPLK1 in tumour cell it is tired and is better than initial 100-1000 doubly, and infectious titer does not have considerable change in normal cell, and the result shows that fully this recombination adenovirus construction body has the characteristic of duplicating at specifically inside tumor cell.
2, the evaluation of the external selective inactivation tumour cell PLK1 expression characterization of recombination adenovirus construction body
The purpose of this experiment is to identify that Δ 923-931ADV5/ASPLK1 recombinant adenovirus is in the influence to a series of tumours and normal cell PLK1 expression, it is A549 that cell is selected in experiment for use, Hela, human osteoblast cell's oncocyte be U-20S (P53+, RB-), the metastatic human adenoma cell is HS700T (P53-, RB-), and CCL188 DLD-1 (P53-, RB-), MCF-7 (P53+, RB+).The clone of selecting for use has different P53, RB gene phenotype; Have different tissues-derivedly, so experimental result can be represented different types of tumors.The normal cell of selecting for use is lung tracheole epithelial cell, prostate epithelial cell, the BMNC in the vascular endothelial cell in former generation, former generation, selects for use principle to be: the normal tissue cell that will contact a large amount of adenovirus after the intravenous administration.
In 24 orifice plate culture dish, plant 1 * 10
5Tumour or normal bone marrow mononuclearcell, nutrient solution are 10%FBS DMEM, and by second day, cell should be 2 * 10
5, about 70% cytogamy is inhaled and is removed liquid, and adding reaches 70% required MOI and is diluted to 100 μ l adding, rocks liquid gently 3 times, at 37 ℃, 5%CO
2In hatched 90 minutes.
Add and to contain 1%FBS DMEM substratum, cell is positioned over 37 ℃ of 5%FBS DMEM substratum to 1ml, cell is positioned in 37 ℃, 5%CO2 hatched 3-10 days, extract the variation that total protein of cell detects the PLK1 protein expression level to 1ml.
Experimental result shows, recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 selective inactivation tumour cell PLK1 protein expression is to can not detection level, and this recombination adenovirus construction body is that the PLK1 protein expression does not have obvious influence to normal control cells simultaneously.The result fully shows recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 selective inactivation tumour cell PLK1 expression of gene.
3, recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 anti-tumor in vivo CHARACTERISTICS IDENTIFICATION tumour cell animal model: select the MCF-7 tumor growth good, the better tumor animal of overall health of patients, the cervical vertebra dislocation is put to death.Aseptic condition takes out down the knurl piece, cuts into the MCF-7 knurl piece in 1-2mm footpath with scalpel, and trochar is inoculated in the nude mouse bilateral, the visible tumour in an about week laboratory animal oxter, back, when tumor growth to 6-7mm, by knurl volume size hierarchical grouping.Every group of 5-8 animal is with 1 * 10
8Injection in the direct tumour of pfu adenovirus, continuous 5 days, the treatment back was with vernier caliper measurement tumour length and width footpath, and (90 days or gross tumor volume are greater than 1cm until the experiment terminal point
3).
Experimental result shows that when the experiment terminal point, positive control adenovirus wild-type adenovirus hominis 5 tumor control rates are 80% ± 2%; Replication-defective adenoviral (ADV-TK) tumor control rate is-50% ± 2%; Recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 tumor control rate is 95% ± 4%, and the result shows that fully recombination adenovirus construction body 923-931ADV5/ASPLK1 has clear and definite anti-tumor in vivo effect.
The recombination adenovirus construction body intravenous administration: select tumor growth good, the better tumor animal of overall health of patients, the cervical vertebra dislocation is put to death.Aseptic condition takes out down the knurl piece, cuts into the knurl piece in 1-2mm footpath with scalpel, and trochar is inoculated in the nude mouse bilateral, the visible tumour in an about week laboratory animal oxter, back, when tumor growth to 4-5mm, by knurl volume size hierarchical grouping.Every group of 5-8 animal is with 1 * 10
8The intravenous injection of pfu adenovirus, continuous 5 days, treatment back was with vernier caliper measurement tumour length and width footpath, and (60 days or gross tumor volume are greater than 1cm until the experiment terminal point
3), experimental result shows that when the experiment terminal point, positive control adenovirus wild-type adenovirus hominis 5 tumor control rates are 60% ± 2%; Replication-defective adenoviral (ADV-TK) tumor control rate is-70% ± 2%: recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 tumor control rate is 96% ± 4%, and the result shows that fully recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 intravenous administration has clear and definite anti-tumor in vivo effect.
The recombination adenovirus construction body intravenous administration suppresses the tumour micrometastasis: (catalog number (Cat.No.): HTB-26) tumor growth is good for ATCC, U.S.A, the better tumor animal of overall health of patients, cervical vertebra dislocation execution to select MDA-MB-231.Aseptic condition takes out down the knurl piece, cuts into the knurl piece in 1-2mm footpath with scalpel, and trochar is inoculated in nude mice breast portion, the visible tumour in an about week laboratory animal oxter, back, when tumor growth to 4-5mm, by the big or small hierarchical grouping of knurl volume.Every group of 5-8 animal is with 1 * 10
8The intravenous injection of pfu adenovirus, continuous 5 days, treatment back was with vernier caliper measurement tumour length and width footpath, and (90 days or gross tumor volume are greater than 1.2cm until the experiment terminal point
3), take out tumour, tracheae, lymphonodi pulmonales, the pathology detection micrometastasis.Experimental result shows that when the experiment terminal point, positive control adenovirus wild-type adenovirus hominis 5 tumor control rates are 60% ± 2%, and the incidence of metastases is 45% ± 5%; Replication-defective adenoviral (ADV-TK) tumor control rate is-70% ± 2%, and the incidence of metastases is 100%; Recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 tumor control rate is 93% ± 5%, and the incidence of metastases is 0%.The result shows that fully recombination adenovirus construction body 923-931ADV5/ASPLK1 intravenous administration has the effect of clear and definite anti-tumor in vivo and inhibition metastases.
Claims (4)
1. recombination adenovirus construction body, its technical characterictic is: this construct has lacked V-type adenovirus 923-931 position nucleotide sequence ctt acc tgc, this sequence encoding E1A protein 12 2 to 124 amino acids, simultaneously, it has lacked V-type adenovirus E3 district 28532-29360 position Nucleotide, introduce a ClaI restriction enzyme site in this disappearance zone, and in the ClaI restriction enzyme site, inserting patent specification accompanying drawing 5DNA sequence table 28560-29328 position nucleotide sequence, other genome structure and wild-type V-type adenovirus are identical.
2. make up the method for the described recombination adenovirus construction body of claim 1, it is characterized in that: with 923-931 position, the coding region nucleotide sequence ctt acctgc of E1A in the pcr amplification fixed point deletion techno-absence pXC1 plasmid, form new carrier Δ 923-931pXC1, Δ 923-931pXC1 plasmid and shuttle vectors pBHGE3 cotransfection 293 cells filter out the recombination adenovirus construction body Δ 923-931ADV5 that expresses E1A mutant functional protein; Adopt pcr amplification fixed point deletion techno-absence V-type adenovirus E3 district 28532-29360 position Nucleotide, and at ClaI restriction enzyme site of this disappearance zone introducing, form new carrier pCDNA3.1-Δ E3, insert patent specification accompanying drawing 5DNA sequence table 28560-29328 position nucleotide sequence at ClaI restriction enzyme site place, form new carrier pCDNA3.1-Δ E3/ASPLK1; Extract the DNA that contains terminal protein with Δ 923-931ADV5, cut with the EcoRI enzyme, with carrier pCDNA3.1-Δ E3/ASPLK1 fragment cotransfection 293 cells that cut out with the EcoRI enzyme, filter out the recombination adenovirus construction body Δ 923-931ADV5/ASPLK1 that expresses E1A mutant functional protein.
3. the described recombination adenovirus construction body of claim 1 is used for the application of the medicine of oncotherapy in preparation.
4. the described recombination adenovirus construction body of claim 1 is in the purposes of preparation in the gene therapy vector.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03126758 CN1237177C (en) | 2003-06-05 | 2003-06-05 | Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent |
| US10/860,630 US20050079158A1 (en) | 2003-06-05 | 2004-06-03 | Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03126758 CN1237177C (en) | 2003-06-05 | 2003-06-05 | Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1552878A CN1552878A (en) | 2004-12-08 |
| CN1237177C true CN1237177C (en) | 2006-01-18 |
Family
ID=34321994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03126758 Expired - Lifetime CN1237177C (en) | 2003-06-05 | 2003-06-05 | Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1237177C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102206613A (en) * | 2010-12-26 | 2011-10-05 | 周剑峰 | Acquisition and use of tumor-selective replicative adenovirus - thymidine kinase gene construct |
| CN102719437A (en) * | 2012-07-11 | 2012-10-10 | 潍坊医学院 | Application of mediated PLK1 RNAi (polo-like kinase-1 ribonucleic acid interference) of lentivirus vector in treatment of esophageal squamous carcinoma metastasis |
-
2003
- 2003-06-05 CN CN 03126758 patent/CN1237177C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1552878A (en) | 2004-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8273344B2 (en) | Recombinant adeno-associated virus expressing human antisense gene CyP2J2 and its preparation methods | |
| JP7159304B2 (en) | Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and their use for medicaments for the treatment of tumors and/or cancers | |
| JP7378840B2 (en) | Oncolytic virus expressing interferon and its application | |
| CN112912389B (en) | Oncolytic virus or antigen presenting cell mediated cancer treatment using type I interferon and CD40 ligand | |
| JP6014029B2 (en) | REIC expression adenovirus vector | |
| CN102286433A (en) | Obtainment and application of novel oncolytic adenovirus-thymidine kinase genetic construct | |
| JP6001535B2 (en) | Oncolytic measles virus | |
| CN102206613A (en) | Acquisition and use of tumor-selective replicative adenovirus - thymidine kinase gene construct | |
| ZA200500047B (en) | Tumor-lysing virus growing selectively in tumor cells | |
| CN101058809B (en) | Use of humanization modified rat ING4 gene and adenovirus expression vectors in preparing medicine for treating lung cancer | |
| CN1237177C (en) | Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent | |
| CN1272440C (en) | Use and constructing method for anticancer recombined gland virus with tumour cell PLK1 as target of medicine | |
| CN1243099C (en) | Use and obtain of inactivating lumour CHK1 gene anticancer recombined gland virus constituent | |
| CN1237178C (en) | Use and constructing plan of anticancer recombined gland virus with tumour CHK1 as target of medicine | |
| CN110387353B (en) | Coxsackie group B virus for treating tumor | |
| CN114917325B (en) | Application of human soluble TIM-4 protein in preparation of antitumor drugs | |
| WO2016187908A1 (en) | Recombinant oncolytic adenovirus and application thereof | |
| US20050079158A1 (en) | Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof | |
| US20130095558A1 (en) | Process for producing recombinant human endostatin adenovirus | |
| RU2730657C1 (en) | Anti-tumour agent based on recombinant vaccinia virus strain and method for production thereof | |
| CN1769433B (en) | Recombinant vesicular stomatitis virus and its uses | |
| CN1177057C (en) | Recombinant of viral vector and human tumor suppressor gene, and use thereof | |
| US20050271622A1 (en) | Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof | |
| CN110656109B (en) | Application of Stat3, HBx, Stat3-HBx targeting CRISPR/Cas vector in preparation of HBV related liver cancer drugs | |
| Turrell et al. | A herpesvirus saimiri-based vector expressing TRAIL induces cell death in human carcinoma cell lines and multicellular spheroid cultures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhou Qi Document name: Notice of conformity |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhou Qi Document name: Notification to Pay the Fees |
|
| ASS | Succession or assignment of patent right |
Owner name: ZHUHAI PEISHENG BIOENGINEERING CO., LTD. Free format text: FORMER OWNER: AONIKESI GENE TECHNOLOGY CO., LTD., SHENZHEN CITY Effective date: 20090417 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090417 Address after: Sanzao town Jinwan District Zhuhai anjitire Road No. 445 Patentee after: Zhuhai Pearson Biological Engineering Co.,Ltd. Address before: Room 2, 201A, a bio incubator building, central high tech Zone, Shenzhen Patentee before: SHENZHEN AONIKESI GENE TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20211201 Address after: 430000 room 579, building B1, biological innovation park, No. 666, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, Hubei Province Patentee after: WUHAN KAIDEWEISI BIOTECHNOLOGY CO.,LTD. Address before: No. 445, Anji Middle Road, Sanzao Town, Jinwan District, Zhuhai Patentee before: Zhuhai Pearson Biological Engineering Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060118 |
|
| CX01 | Expiry of patent term |